A5000365272- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Urticaria and Related Conditions
- Autoimmune Bullous Skin Diseases
- Hemophilia Treatment and Research
- Vitamin K Research Studies
- Food Allergy and Anaphylaxis Research
- Mast cells and histamine
- Allergic Rhinitis and Sensitization
- Contact Dermatitis and Allergies
- Peptidase Inhibition and Analysis
- Corneal surgery and disorders
- Ophthalmology and Visual Impairment Studies
- Higher Education Teaching and Evaluation
- Educational Technology in Learning
- Liver Disease Diagnosis and Treatment
- Drug-Induced Adverse Reactions
- Enzyme function and inhibition
- Blood Coagulation and Thrombosis Mechanisms
- Advanced Fluorescence Microscopy Techniques
- Chronic Myeloid Leukemia Treatments
- Glaucoma and retinal disorders
- Eosinophilic Esophagitis
- Eosinophilic Disorders and Syndromes
- Plasmonic and Surface Plasmon Research
- Intraocular Surgery and Lenses
Hospital La Paz Institute for Health Research
2016-2025
Centre for Biomedical Network Research on Rare Diseases
2016-2025
Joint Base San Antonio
2025
Hospital Universitario La Paz
2014-2024
University of Alicante
2011-2024
Universidad de Sevilla
2021-2024
Instituto de Biomedicina de Sevilla
2014-2024
Centro de Investigación Biomédica en Red
2015-2024
Hospital Universitario Virgen del Rocío
2016-2024
Consejo Superior de Investigaciones Científicas
2007-2024
We published the Canadian 2003 International Consensus Algorithm for Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) updated this as angioedema: a current state-of-the-art review: Hungarian 2007 Angioedema. To update Therapy (circa 2010). The Network (CHAEN)/Réseau Canadien d'angioédème héréditaire (RCAH) http://www.haecanada.com cosponsors University Calgary Society Allergy Clinical Immunology (with an unrestricted educational grant from...
Angioedema is defined as localized and self-limiting edema of the subcutaneous submucosal tissue, due to a temporary increase in vascular permeability caused by release vasoactive mediator(s). When angioedema recurs without significant wheals, patient should be diagnosed have distinct disease. In absence accepted classification, different types are not uniquely identified. For this reason, European Academy Allergy Clinical Immunology gave its patronage consensus conference aimed at...
To cite this article: Cicardi M, Bork K, Caballero T, Craig Li HH, Longhurst H, Reshef A, Zuraw B on behalf of HAWK ( H ereditary A ngioedema International W or k ing Group). Evidence‐based recommendations for the therapeutic management angioedema owing to hereditary C1 inhibitor deficiency: consensus report an Working Group. Allergy 2012; 67 : 147–157. Abstract Angioedema deficiency (HAE) is a rare, life‐threatening, disabling disease. In last 2 years, results well‐designed and controlled...
Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis effective therapy are critical. This revision update of the global WAO/EAACI guideline on management HAE provides up-to-date guidance HAE. For this guideline, an international panel experts reviewed existing evidence, developed 28 recommendations, established consensus by online DELPHI process. The goal these recommendations to help physicians their patients in making rational decisions with deficient C1...
Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction II) of the C1 inhibitor protein. In phase 2 trial, use CSL830, nanofiltered preparation that suitable for subcutaneous injection, resulted in functional levels activity would be expected to provide effective prophylaxis attacks.We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 3 trial evaluate efficacy and safety...
Hereditary angioedema (HAE) is a rare but potentially life-threatening disease marked by spontaneous, recurrent attacks of swelling. The broad range consequences HAE on patients' lives not well understood. study objective was to comprehensively characterize the burden illness and impact types I II from patient perspective. Burden Illness Study in Europe conducted Spain, Germany, Denmark assess real-world experience perspective via one-time survey, which included items clinical...
Hereditary angioedema (C1 inhibitor deficiency, HAE) is associated with intermittent swellings which are disabling and may be fatal. Effective treatments available these most useful when given early in the course of swelling. The requirement to attend a medical facility for parenteral treatment results delays. Home therapy offers possibility earlier better symptom control, enabling patients live more healthy, productive lives. This paper examines evidence patient-controlled home acute...
Background Attacks of hereditary angioedema (HAE) are unpredictable and, if affecting the upper airway, can be lethal. Icatibant is used for physician- or patient self-administered symptomatic treatment HAE attacks in adults. Its mode action includes disruption bradykinin pathway via blockade B2 receptor. Early believed to shorten attack duration and prevent severe outcomes; however, evidence support these benefits lacking. Objective To examine impact timing icatibant administration on...
Hereditary angioedema (HAE) due to C1 inhibitor deficiency is a rare but serious and potentially life-threatening disease marked by spontaneous, recurrent attacks of swelling. The study objective was characterize direct indirect resource utilization associated with HAE from the patient perspective in Europe. conducted Spain, Germany, Denmark assess real-world experience via cross-sectional survey patients, including during between for patients their caregivers over past 6 months. A...
<h2>Abstract</h2><h3>Background</h3> Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) causes swelling in the skin and upper airways pain abdomen because of mucosal swelling. C1-INH-HAE is frequently misdiagnosed, leading delays diagnosis, inadequate treatment, unnecessary procedures. <h3>Objective</h3> To evaluate history misdiagnosis patients participating Icatibant Outcome Survey (IOS). <h3>Methods</h3> The IOS an observational study which safety effectiveness icatibant...
<h3>Background</h3> For the prevention of attacks hereditary angioedema (HAE), efficacy and safety subcutaneous human C1-esterase inhibitor (C1-INH[SC]; HAEGARDA, CSL Behring) was established in 16-week Clinical Study for Optimal Management Preventing Angioedema with Low-Volume Subcutaneous C1-Inhibitor Replacement Therapy (COMPACT). <h3>Objective</h3> To assess long-term safety, occurrence attacks, use rescue medication C1-INH(SC). <h3>Methods</h3> Open-label, randomized, parallel-arm...
Background and aim: Eosinophilic esophagitis can be associated with a wide range of endoscopic patterns. The aim the present case series report is to describe classify appearances before after corticoid therapy in relation histopathology manometry.